Neozene, Inc

New warning signs of being infected with COVID-19 have been identified, Colorado State University scientists revealed. http://www.neozene.com/new-early-warning-signs-covid-infect

The White House and many Americans have pinned their hopes for defeating the COVID-19 pandemic on a vaccine being developed at warp speed. But some scientific experts warn they’re all expecting too much, too soon. http://www.neozene.com/scientists-first-covid-shots-may-le/

In a recent press conference, Health and Human Services Secretary Alex Azar acknowledged that Pfizer is facing production hurdles with its mRNA vaccine. http://www.neozene.com/feds-pfizer-vaccine-faces-various-c/

The U.K.’s monumental approval for Pfizer and BioNTech’s COVID-19 vaccine turned heads worldwide, but one of the leading voices in the U.S. pandemic response argues the country’s regulators acted too quickly. http://www.neozene.com/fauci-cautious-uk-speedy-vaccine-app

We wish you and your loved ones a happy and safe Thanksgiving! What are you thankful for this year?

Wednesday, federal health officials unveiled a detailed timeline that provides some clues about when most Americans can expect to be vaccinated. www.neozene.com/feds-lay-ambitious-plan-vaccine-rollout

On Monday, Pfizer released stellar early results from its COVID vaccine trial, but concerns about cold chain requirements quickly tempered it. In response, Pfizer has a new plan to distribute the vaccine: make it in a powder form. http://www.neozene.com/pfizer-release-covid-vaccine-powder-

The COVID-19 pandemic has millennials worriedand that has them planning to buy more prescription drugs in the future, new research finds. http://www.neozene.com/study-millennials-expect-spend-meds/

A weeks-long feud between the White House and FDA over COVID-19 vaccine guidelines took another turn Tuesday as the agency released vaccine recommendations despite efforts by the White House to keep them under wraps. http://www.neozene.com/new-fda-vaccine-rules-nix-pre-elect/

Genentech has secured a global license to neoantigen cancer vaccines developed by Vaccibody. http://www.neozene.com/genentech-pays-200m-vaccibodys-phas/

A suite of drugmakers looked to monoclonal antibodies to fight the immune system overreaction seen in severe COVID patients. Most of those candidates had mixed success, but Humanigen is pressing aheadand it’s bringing on partners. http://www.neozene.com/manufacturing-monoclonal-antibody-co

Reputation and trust are at an all-time high as consumers look to drugmakers for vaccines and treatments that can clear a path out of the COVID-19 pandemic. But don't break out the champagne, just yet. http://www.neozene.com/pandemic-best-chance-big-pharma-fix/

As coronavirus vaccines edge closer to market, the next question is how pharma companies and public health authorities will convince people to get them. http://www.neozene.com/analysts-personal-stories-likely-in/

A series of clinical trials from around the world provide definitive data that corticosteroids should be first-line treatment for critically ill patients with COVID-19, two researchers wrote in a JAMA editorial. http://www.neozene.com/study-confirms-steroids-save-ill-co/

Moderna’s mRNA COVID-19 vaccine candidate was the first U.S. shot to enter late-stage testing, but that doesn’t necessarily mean it has the brightest future of all. http://www.neozene.com/analyst-moderna-covid-19-vaccine-ou/

Despite hundreds of potential therapies for COVID-19 looking to make their case, very few have crossed the finish line. One promising candidate, Regeneron’s two-antibody cocktail, has earned early plauditsand now a pharma giant is jumping aboard to boost manufacturing in a big way. http://www.neozene.com/two-pharma-giants-join-forces-tripl/

A respected pharma analyst has recently announced his belief that the total market for COVID-19 vaccines would be worth $100 billion in sales and $40 billion in post-tax profits. Leading the way is Moderna, expected to supply 40% of the total market. http://www.neozene.com/covid-19-vaccine-players-will-likel/

With leading COVID-19 vaccines in late-stage testing, companies have been inking supply deals with the U.S. government for a quick rollout if their programs succeed. Now, Johnson & Johnson is getting into the act. http://www.neozene.com/johnson-johnson-promises-100m-coron/

There is a tiny possibility that a viable COVID vaccine could be ready before Election Day. It's a possibility that is filling many public health experts with dread. http://www.neozene.com/experts-fear-politics-will-cloud-va/

Many biopharma companies have been talking up the potential of authorized COVID-19 vaccines by year-end. But experts caution that a rushed timeline could be counterproductive for adoption. http://www.neozene.com/widespread-covid-19-vaccine-adoptio/